Rodman & Renshaw Initiates Zalicus Coverage: Market Outperform, $5 PT

Rodman & Renshaw initiated Zalicus ZLCS coverage with a Market Outperform rating and $5 price target in a research report published today. In the report, Rodman & Renshaw states, "We believe that the company's drug combination approach and its innovative ion channel modulator discovery platform provide a renewable source of drug candidates throughout the development spectrum." Shares of Zalicus closed today at $2.60, down 1.14% from Tuesday's market close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationAnalyst RatingsRodman & Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!